Is prostate cancer different in black men? Answers from 3 natural history models

Cancer

Volumn 123, Issue 12, 2017, Pages 2312-2319

  Tsodikov, Alex ^a   Gulati, Roman ^b   de Carvalho, Tiago M ^c   Heijnsdijk, Eveline A M ^c   Hunter Merrill, Rachel A ^b   Mariotto, Angela B ^d   de Koning, Harry J ^c   Etzioni, Ruth ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer epidemiology; mass screening; natural history; prostate specific antigen; prostatic neoplasms; racial disparities; statistical methods and models

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGED; ARTICLE; BLACK PERSON; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; HISTORY; HUMAN; MALE; METASTASIS; ONSET AGE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; AFRICAN AMERICAN; BLOOD; CANCER REGISTRY; COMPUTER SIMULATION; DISEASE COURSE; EARLY CANCER DIAGNOSIS; ETHNOLOGY; PATHOLOGY; PREVALENCE; PROSTATIC NEOPLASMS; RISK; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AFRICAN AMERICANS; COMPUTER SIMULATION; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; MALE; MODELS, STATISTICAL; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; SEER PROGRAM; UNITED STATES;

EID: 85018861259     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30687     Document Type: Article

References (31)

1. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007;177:444-449.
2. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004;171:1504-1507.
3. Schwartz K, Powell IJ, Underwood W 3rd, George J, Yee C, Banerjee M. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology. 2009;74:1296-1302.
4. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997;94:3320-3323.
5. Bensen JT, Xu Z, Smith GJ, Mohler JL, Fontham ET, Taylor JA. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate. 2013;73:1-22.
6. Faisal FA, Sundi D, Tosoian JJ, et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location. Eur Urol. 2016;70:14-17.
7. Moul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996;155:1667-1673.
8. Faisal FA, Sundi D, Cooper JL, et al. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. Urology. 2014;84:1434-1441.
9. Barocas DA, Gray DT, Fowke JH, et al. Racial variation in the quality of surgical care for prostate cancer. J Urol. 2012;188:1279-1285.
10. Shavers VL, Brown ML, Potosky AL, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004;19:146-155.
11. Klabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998;36:1337-1348.
12. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64:1171-1176.
13. Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012;118:4280-4289.
14. Metcalfe C, Evans S, Ibrahim F, et al. Pathways to diagnosis for black men and white men found to have prostate cancer: the PROCESS cohort study. Br J Cancer. 2008;99:1040-1045.
15. Powell IJ, Banerjee M, Sakr WA, et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer. 1999;85:472-477.
16. Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomarkers Prevent. 2014;23:1505-1511.
17. Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics. 2010;11:707-719.
18. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:68-878.
19. Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med. 2006;25:2846-2866.
20. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158:145-153.
21. Heijnsdijk EA, de Carvalho TM, Auvinen A, et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data [serial online]. J Natl Cancer Inst. 2015;107:366.
22. Mariotto A, Etzioni R, Krapcho M, Feuer EJ. Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 2007;109:1877-1886.
23. van Buuren S, Groothuis-Oudshoorn K. Multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1-67.
24. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175-181.
25. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118:5955-5963.
26. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010;183:1792-1796.
27. Moyer VA, US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.
28. Wolf AM. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70-98.
29. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419-426.
30. Hall L, Bullock AD, Brown AL, Colditz G. Prostate cancer isn't colorblind. New York Times. July 27, 2016:A27.
31. Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Screening men at increased risk for prostate cancer diagnosis: model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev. 2017;26:222-227.